Amid the topmost stocks in today’s market is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). BioMarin Pharmaceutical Inc. had a market cap of 17055.41, indicating that it has a good hold on the market value of the shares outstanding. The current market cap of BioMarin Pharmaceutical Inc. exhibits the basic determinant of asset allocation and risk-return parameters for its stocks.
The P/E of BioMarin Pharmaceutical Inc. is currently valued at allowing its investors to analyze the company’s stock valuation and its shares relative to the income of the company that it makes. With the constructive P/E value of BioMarin Pharmaceutical Inc., the investors are able to forecast the positive earnings growth of the company.
The forward P/E of BioMarin Pharmaceutical Inc. is at signifying the uses of estimated net earnings over the next 12 months. Investors will be getting a good grip in comparing the current earnings of the company to estimated future earnings.
With its low price-to-sales ratio of 19.09, the company is evidently a better investment since the investors are paying a lower amount for each unit of sales. However, the company sales do not necessarily expose the entire picture, as it might be unprofitable with a low P/S ratio.
The price-to-book ratio of 7.42 for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) implies that investors are highly hopeful for the organization to create more value from the given set of assets. The market value of the firm’s assets are considerably higher in contrast to their accounting value. The current P/B amount of BioMarin Pharmaceutical Inc. best indicates the value approach in differentiating good from the bad. The ratio also provides a clue to how much investors are paying for what would be left if the company went bankrupt immediately.
The target payout ratio for BioMarin Pharmaceutical Inc. is currently measuring at , outlining what size the company’s dividends should be. It also demonstrates a stable dividend policy for BioMarin Pharmaceutical Inc. connected to the long-run, with viable earnings.
The EPS for BioMarin Pharmaceutical Inc. is valued at -1.98 with an EPS growth this year at 28.10%. The company’s EPS growth for the following year is valued at -301.90%, indicating an EPS value of 37.13% for the past 5 years, and an EPS value of 25.00% for the coming five years.
BioMarin Pharmaceutical Inc.’s sales for the past 5 years rolls at 18.30%, exhibiting an EPS growth from quarter-to-quarter at . The sales growth of the company is 18.40% at the moment, indicating the average sales volume of the company’s products and services that have typically improved year-to-year.
Company’s existing stock price is at 105.02 with a change in price of -0.71%. As of now, the target price for the company is measuring at 147.88. BioMarin Pharmaceutical Inc.’s ROA is rolling at -9.20%, following the ROI of -4.70%. Quick and current ratio is valued at 2.3 and 3 respectively.